Once-daily gastroretentive gabapentin for postherpetic neuralgia: Integrated efficacy, time to onset of pain relief and safety analyses of data from two phase 3, multicenter, randomized, double-blind, placebo-controlled studies

Journal of Pain and Symptom Management

Volumn 46, Issue 2, 2013, Pages 219-228

  Rauck, Richard L ^a   Irving, Gordon A ^b   Wallace, Mark S ^c   Vanhove, Geertrui F ^d   Sweeney, Michael ^d  

^a Center for Clinical Research   (United States)

^b Swedish Pain and Headache Center   (United States)

^c Thornton Hospital   (United States)

^d Pharmacokinetics Depomed Inc   (United States)

Author keywords

gastroretentive gabapentin; onset of pain relief; Postherpetic neuralgia

Indexed keywords

ANTIDEPRESSANT AGENT; CYCLOOXYGENASE 2 INHIBITOR; GABAPENTIN; PLACEBO; SEROTONIN UPTAKE INHIBITOR;

ADULT; AGED; ANALGESIA; ARM FRACTURE; ARTICLE; BODY WEIGHT; CELLULITIS; CHRONIC PANCREATITIS; CONTROLLED STUDY; DIARRHEA; DIZZINESS; DRUG DOSE TITRATION; DRUG EFFICACY; DRUG FATALITY; DRUG INDUCED HEADACHE; DRUG RETENTION; DRUG SAFETY; FEMALE; HEART ATRIUM FIBRILLATION; HEART FAILURE; HEART INFARCTION; HEMATURIA; HUMAN; INGUINAL HERNIA; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; OSTEOCHONDROSIS; OUTCOME ASSESSMENT; PAIN ASSESSMENT; PANCOAST TUMOR; PERIPHERAL EDEMA; PHASE 3 CLINICAL TRIAL; PNEUMONIA; POSTHERPETIC NEURALGIA; RANDOMIZED CONTROLLED TRIAL; RATING SCALE; RHINOPHARYNGITIS; SCORING SYSTEM; SIDE EFFECT; SOMNOLENCE; THROMBOPHLEBITIS; TREATMENT DURATION; XEROSTOMIA;

EID: 84882455690     PISSN: 08853924     EISSN: 18736513     Source Type: Journal    
DOI: 10.1016/j.jpainsymman.2012.07.011     Document Type: Article

References (19)

1. R. Harpaz, I.R. Ortega-Sanchez, J.F. Seward Advisory Committee on Immunization Practices (ACIP) Centers for Disease Control and Prevention (CDC) Prevention of herpes zoster: recommendations of the Advisory Committee on Immunization Practices (ACIP) MMWR Recomm Rep 57 2008 1 30
2. B.P. Yawn, P. Saddier, and P.C. Wollan A population-based study of the incidence and complication rates of herpes zoster before zoster vaccine introduction Mayo Clin Proc 82 2007 1341 1349
3. J.W. Gnann Jr., and R.J. Whitley Clinical practice. Herpes zoster N Engl J Med 347 2002 340 346
4. M. Rowbotham, N. Harden, B. Stacey, P. Bernstein, and L. Magnus-Miller Gabapentin for the treatment of postherpetic neuralgia: a randomized controlled trial JAMA 280 1998 1837 1842
5. A.S. Rice, S. Maton Postherpetic Neuralgia Study Group Gabapentin in postherpetic neuralgia: a randomised, double blind, placebo controlled study Pain 94 2001 215 224
6. S. Schwartz, V. Fonseca, and B. Berner Efficacy, tolerability, and safety of a novel once-daily extended-release metformin in patients with type 2 diabetes Diabetes Care 29 2006 759 764
7. GRALISE® (gabapentin) prescribing information 2012 Depomed, Inc. Menlo Park, CA Available from http://www.gralise.com Accessed April 12, 2012
8. B.H. Stewart, A.R. Kugler, P.R. Thompson, and H.N. Bockbrader A saturable transport mechanism in the intestinal absorption of gabapentin is the underlying cause of the lack of proportionality between increasing dose and drug levels in plasma Pharm Res 10 1993 276 281
9. T. Gordi, E. Hou, S. Kasichayanula, and B. Berner Pharmacokinetics of gabapentin after a single day and at steady state following the administration of gastric-retentive-extended-release and immediate-release tablets: a randomized, open-label, multiple-dose, three-way crossover, exploratory study in healthy subjects Clin Ther 30 2008 909 916
10. C. Chen, V.E. Cowles, and E. Hou Pharmacokinetics of gabapentin in a novel gastric-retentive extended-release formulation: comparison with an immediate release formulation and effect of dose escalation and food J Clin Pharmacol 51 2011 346 358
11. M.S. Wallace, G. Irving, and V.E. Cowles Gabapentin extended-release tablets for the treatment of patients with postherpetic neuralgia: a randomized, double-blind, placebo-controlled, multicentre study Clin Drug Investig 30 2010 765 776
12. C. Sang, R. Sathyanarayana, M. Sweeney DM-1796 Study Investigators Gastroretentive gabapentin (G-GR) formulation reduces intensity of pain associated with postherpetic neuralgia (PHN) Clin J Pain 29 2013 281 288 Available from http://journals.lww.com/clinicalpain/Abstract/publishahead/ Gastroretentive-Gabapentin-G-GR-Formulation.99733.aspx Accessed July 16, 2012
13. W. Guy ECDEU assessment manual for psychopharmacology (DHEW Publication No. ADM 76-338) 1976 U.S. Government Printing Office Washington, DC
14. U. Sharma, T. Griesing, B. Emir, and J.P. Young Jr. Time to onset of neuropathic pain reduction: a retrospective analysis of data from nine controlled trials of pregabalin for painful diabetic peripheral neuropathy and postherpetic neuralgia Am J Ther 17 2010 577 585
15. B.R. Stacey, J.A. Barrett, E. Whalen, K.F. Phillips, and M.C. Rowbotham Pregabalin for postherpetic neuralgia: placebo-controlled trial of fixed and flexible dosing regimens on allodynia and time to onset of pain relief J Pain 9 2008 1006 1017
16. R.H. Dworkin, A.T. Corbin, and J.P. Young Jr. Pregabalin for the treatment of postherpetic neuralgia: a randomized, placebo-controlled trial Neurology 60 2003 1274 1283
17. R. Freynhagen, P. Busche, and C. Konrad Effectiveness and time to onset of pregabalin in patients with neuropathic pain [in German] Schmerz 20 2006 285 288 290-292
18. J.T. Farrar, J.P. Young Jr., and L. LaMoreaux Clinical importance of changes in chronic pain intensity measured on an 11-point numerical pain rating scale Pain 94 2001 149 158
19. R.A. Moore, P.J. Wiffen, S. Derry, and H.J. McQuay Gabapentin for chronic neuropathic pain and fibromyalgia in adults Cochrane Database Syst Rev 3 2011 CD007938